Fiche société
The Affiliated Hospital of Xuzhou Medical University
Traitements, essais et publications liés.
Traitements5programmes
Essais3liés
Publications2liées
SourceDBlocale
Traitements
5| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). | Lupus, Myasthénie | Non applicable | China | À vérifier | |
| UCAR-T cellsThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases. | Lupus | NA | Immunomodulation + Thérapie cellulaire | China | À vérifier |
| UCAR-T cellsThis is an investigator-initiated trial to evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in With Relapse/Refractory Autoimmune Diseases. | Lupus | NA | Thérapie cellulaire | China | À vérifier |
| HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). | Lupus | Phase 1 | China | À vérifier | |
| HN2302 InjectionThis is an open-label, single-arm study designed to evaluate the safety and preliminary efficacy of HN2302 in patients with autoimmune diseases, including systemic lupus erythematosus (SLE) and systemic sclerosis (SSc). | Myasthénie | Non applicable | China | À vérifier |
Essais cliniques
3| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| HN2302 Injection | Myasthénie | Non applicable | NCT07413835 | Efficacy and Safety of HN2302 in Refractory Myasthenia Gravis(MG) | RECRUITING |
| HN2302 Injection | Lupus | Phase 1 | NCT07523282 | AID — Safety and Preliminary Efficacy of HN2302 in Patients With Autoimmune Diseases | NOT_YET_RECRUITING |
| UCAR-T cells | Lupus | NA | NCT07155369 | UCAR T-cell Therapy Targeting CD19/ BCMA in Patients With Relapse/ Refractory Autoimmune Diseases | ACTIVE_NOT_RECRUITING |
Publications
2| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| UCAR-T cells | CRISPR/Cas9-engineered universal CD123/B7-H3 tandem CAR-T cell for the treatment of acute myeloid leukemia. | Chinese medical journal | ||
| UCAR-T cells | A novel triple-knockout allogeneic BCMA CAR T cell therapy (CT0590) in multiple myeloma: preclinical and phase I study. | Blood |